147 related articles for article (PubMed ID: 11484983)
1. Serum cytokeratins determination in differentiated thyroid carcinoma.
Appetecchia M; Meçule A; Ducci M; Palma L; Castelli M
J Exp Clin Cancer Res; 2001 Jun; 20(2):253-6. PubMed ID: 11484983
[TBL] [Abstract][Full Text] [Related]
2. Ghrelin in human medullary thyroid carcinomas.
Morpurgo PS; Cappiello V; Verga U; Vicentini L; Vaghi I; Lauri E; Nebuloni M; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):437-41. PubMed ID: 16181236
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
[TBL] [Abstract][Full Text] [Related]
4. Expression of cytokeratin 20 in thyroid carcinomas and peripheral blood detected by reverse transcription polymerase chain reaction.
Weber T; Lacroix J; Weitz J; Amnan K; Magener A; Hölting T; Klar E; Herfarth C; von Knebel Doeberitz M
Br J Cancer; 2000 Jan; 82(1):157-60. PubMed ID: 10638983
[TBL] [Abstract][Full Text] [Related]
5. Measurement of serum PDN-21 (Katacalcin) levels by radioimmunoassay in patients with various thyroid diseases.
Takami H
Exp Clin Endocrinol; 1994; 102(5):370-3. PubMed ID: 7867699
[TBL] [Abstract][Full Text] [Related]
6. uPA receptor expression in benign and malignant thyroid tumors.
Kim SJ; Shiba E; Taguchi T; Tsukamoto F; Miyoshi Y; Tanji Y; Takai S; Noguchi S
Anticancer Res; 2002; 22(1A):387-93. PubMed ID: 12017319
[TBL] [Abstract][Full Text] [Related]
7. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma.
Yu XM; Lo CY; Lam AK; Leung P; Luk JM
Ann Surg; 2008 Mar; 247(3):483-9. PubMed ID: 18376194
[TBL] [Abstract][Full Text] [Related]
8. The role of estimation of the ratio of preoperative serum thyroglobulin to the thyroid mass in predicting the behaviour of well differentiated thyroid cancers.
Sharma AK; Sarda AK; Chattopadhyay TK; Kapur MM
J Postgrad Med; 1996; 42(2):39-42. PubMed ID: 9715297
[TBL] [Abstract][Full Text] [Related]
9. Pancreas cancer-associated antigen (PCAA) in medullary thyroid carcinoma.
Ueno K; Kobayashi T; Shimano T; Matsuura N; Monden T; Takeda T; Tomita N; Mori T
Med J Osaka Univ; 1994 Sep; 43(1-4):17-21. PubMed ID: 7609706
[TBL] [Abstract][Full Text] [Related]
10. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
[TBL] [Abstract][Full Text] [Related]
11. Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.
Hesse E; Musholt PB; Potter E; Petrich T; Wehmeier M; von Wasielewski R; Lichtinghagen R; Musholt TJ
Br J Cancer; 2005 Sep; 93(5):565-70. PubMed ID: 16091757
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of angiogenic growth factors in patients with thyroid gland tumors and parathyroid adenoma.
Veselý D; Astl J; Matucha P; Sterzl I; Betka J
Neuro Endocrinol Lett; 2003 Dec; 24(6):417-9. PubMed ID: 15073567
[TBL] [Abstract][Full Text] [Related]
13. Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma.
Mai KT; Khanna P; Yazdi HM; Perkins DG; Veinot JP; Thomas J; Lamba M; Nair BD
Pathology; 2002 Jun; 34(3):239-44. PubMed ID: 12109784
[TBL] [Abstract][Full Text] [Related]
14. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
15. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma.
Sethi K; Sarkar S; Das S; Rajput S; Mazumder A; Roy B; Patra S; Mohanty B; El-Naggar AK; Mandal M
J Exp Ther Oncol; 2011; 9(3):187-99. PubMed ID: 22070050
[TBL] [Abstract][Full Text] [Related]
16. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma.
Machens A; Holzhausen HJ; Lautenschläger C; Thanh PN; Dralle H
Cancer; 2003 Aug; 98(4):712-9. PubMed ID: 12910514
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma.
Machens A; Holzhausen HJ; Dralle H
Cancer; 2005 Jun; 103(11):2269-73. PubMed ID: 15856429
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A: an additional tumor marker for postoperative recurrence and metastases of medullary thyroid carcinomas?
Franke WG; Pinkert J; Runge R; Bredow J; Wunderlich G; Koch R
Anticancer Res; 2000; 20(6D):5257-60. PubMed ID: 11326706
[TBL] [Abstract][Full Text] [Related]
20. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.
Xu X; Quiros RM; Maxhimer JB; Jiang P; Marcinek R; Ain KB; Platt JL; Shen J; Gattuso P; Prinz RA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5968-79. PubMed ID: 14676122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
